Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes
Hepatocellular carcinoma (HCC) is a highly aggressive and lethal cancer. It is typically asymptomatic at the early stage, with only 10%–20% of HCC patients being diagnosed early enough for appropriate surgical treatment. The delayed diagnosis of HCC is associated with limited treatment options and m...
Main Authors: | Ping Zhao, Xiaoyang Yang, Shibo Qi, Hongguang Liu, Han Jiang, Susan Hoppmann, Qizhen Cao, Mei-Sze Chua, Samuel K. So, Zhen Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2013/759057 |
Similar Items
-
In Vivo Imaging of Xenograft Tumors Using an Epidermal Growth Factor Receptor-Specific Affibody Molecule Labeled with a Near-infrared Fluorophore
by: Haibiao Gong, et al.
Published: (2010-02-01) -
Affibody molecules targeting the epidermal growth factor receptor for tumor imaging applications
by: Friedman, Mikaela
Published: (2008) -
A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts
by: Arutselvan Natarajan, et al.
Published: (2021-08-01) -
Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells
by: Grepper Susan, et al.
Published: (2009-09-01) -
Affibody-Binding Ligands
by: Annalisa Barozzi, et al.
Published: (2020-05-01)